Novavax (NVAX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NVAX Stock Forecast

Novavax stock forecast is as follows: an average price target of $20.33 (represents a 138.90% upside from NVAX’s last price of $8.51) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

NVAX Price Target

The average price target for Novavax (NVAX) is $20.33 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $14.00. This represents a potential 138.90% upside from NVAX's last price of $8.51.

NVAX Analyst Ratings

Buy

According to 18 Wall Street analysts, Novavax's rating consensus is 'Buy'. The analyst rating breakdown for NVAX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).

Novavax Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 18, 2024	Mayank Mamtani	B.Riley Financial	$22.00	$7.58	190.24%	158.52%
Oct 16, 2024	Roger Song	Jefferies	$25.00	$10.15	146.31%	193.77%
Oct 16, 2024	Alec Stranahan	Bank of America Securities	$14.00	$10.45	34.04%	64.51%
Jul 19, 2024	Roger Song	Jefferies	$31.00	$14.36	115.88%	264.28%
May 10, 2024	Vernon Bernardino	H.C. Wainwright	$19.00	$9.94	91.24%	123.27%
Feb 14, 2022	Charles Duncan	Cantor Fitzgerald	$174.00	$80.11	117.20%	1944.65%

The latest Novavax stock forecast, released on Nov 18, 2024 by Mayank Mamtani from B.Riley Financial, set a price target of $22.00, which represents a 190.24% increase from the stock price at the time of the forecast ($7.58), and a 158.52% increase from NVAX last price ($8.51).

Novavax Price Target by Period

	1M	3M	12M
# Anlaysts	-	3	5
Avg Price Target	-	$20.33	$22.20
Last Closing Price	$8.51	$8.51	$8.51
Upside/Downside	-100.00%	138.90%	160.87%

In the current month, the average price target of Novavax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Novavax's last price of $8.51. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 16, 2024	Jefferies	Buy	Buy	Hold
Oct 16, 2024	Bank of America Securities	Neutral	Neutral	Hold
Oct 10, 2024	B. Riley	Buy	Buy	Hold
Jul 19, 2024	Jefferies	Buy	Buy	Hold
May 23, 2024	B. Riley	Buy	Buy	Hold
May 13, 2024	Cowen & Co.	Hold	Hold	Hold
May 10, 2024	Bank of America Securities	Underperform	Neutral	Upgrade
May 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 09, 2023	Raymond James	Market Perform	Outperform	Upgrade
Aug 09, 2023	Evercore ISI		Neutral	Downgrade
Aug 09, 2023	Telsey Advisory		Market Perform	Downgrade
Aug 09, 2023	Needham		Hold	Downgrade
Aug 09, 2023	Wedbush		Neutral	Downgrade
Aug 09, 2023	RBC Capital		Sector Perform	Downgrade
Aug 09, 2023	Wells Fargo		Overweight	Upgrade
May 10, 2023	Barclays	Buy	Buy	Hold
Mar 12, 2023	B. Riley Securities	Buy	Reduce	Downgrade
Dec 30, 2022	H.C. Wainwright	Buy	Buy	Hold
Sep 22, 2022	Raymond James		Market Perform	Initialise
Sep 22, 2022	Benchmark		Hold	Initialise
Sep 22, 2022	J.P. Morgan		Buy	Downgrade
Jul 22, 2022	B. Riley	Buy	Buy	Hold
Jun 18, 2022	B. Riley	Buy	Buy	Hold
Jun 13, 2022	Cantor Fitzgerald	Overweight	Overweight	Hold
Jun 08, 2022	CFRA		Buy	Upgrade
May 20, 2022	Bank of America Securities		Underperform	Initialise
May 12, 2022	B. Riley	Buy	Buy	Initialise
Apr 28, 2022	B. Riley	Buy	Buy	Hold
Apr 26, 2022	B. Riley Securities	Buy	Buy	Hold
Feb 14, 2022	Cantor Fitzgerald	Overweight	Overweight	Hold
Jan 04, 2022	B. Riley	Buy	Buy	Hold
Mar 29, 2021	B. Riley Securities	Buy	Buy	Hold

Novavax's last stock rating was published by H.C. Wainwright on Nov 13, 2024. The company gave NVAX a "Buy" rating, the same as its previous rate.

Novavax Financial Forecast

Novavax Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$186.99M	$424.43M	$80.95M	$287.83M	$734.58M	$185.93M	$703.97M	$222.20M	$178.84M	$298.02M	$447.23M	$279.66M	$157.02M	$35.54M	$3.38M	$8.82M	$2.51M	$3.36M	$3.98M	$9.65M	$5.68M
Avg Forecast	$39.30M	$59.20M	$212.50M	$47.50M	$102.74M	$73.78M	$458.57M	$101.16M	$322.05M	$115.42M	$264.16M	$87.61M	$383.14M	$586.25M	$863.68M	$845.20M	$331.79M	$334.53M	$387.87M	$233.90M	$202.44M	$230.56M	$28.20M	$1.93M	$2.06M	$2.66M	$3.06M	$4.42M	$9.24M	$6.04M
High Forecast	$42.07M	$63.38M	$227.50M	$48.00M	$117.33M	$78.99M	$490.95M	$108.30M	$363.50M	$123.57M	$282.80M	$93.80M	$410.19M	$586.25M	$863.68M	$845.20M	$331.79M	$334.53M	$387.87M	$233.90M	$202.44M	$230.56M	$28.20M	$1.93M	$2.06M	$2.66M	$3.06M	$4.42M	$11.08M	$7.24M
Low Forecast	$37.52M	$56.51M	$202.86M	$46.66M	$94.34M	$70.44M	$437.77M	$96.57M	$290.31M	$110.18M	$252.17M	$83.64M	$365.76M	$586.25M	$863.68M	$845.20M	$331.79M	$334.53M	$387.87M	$233.90M	$202.44M	$230.56M	$28.20M	$1.93M	$2.06M	$2.66M	$3.06M	$4.42M	$7.39M	$4.83M
# Analysts	1	1	1	2	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	16	8	11	7	11	7	7	17	9
Surprise %	-	-	-	-	-	-	-	-	-	1.62%	1.61%	0.92%	0.75%	1.25%	0.22%	0.83%	0.67%	0.53%	0.77%	1.91%	1.38%	0.68%	1.26%	1.75%	4.27%	0.94%	1.10%	0.90%	1.05%	0.94%

Novavax's average Quarter revenue forecast for Dec 23 based on 5 analysts is $322.05M, with a low forecast of $290.31M, and a high forecast of $363.50M. NVAX's average Quarter revenue forecast represents a 72.23% increase compared to the company's last Quarter revenue of $186.99M (Sep 23).

Novavax EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	16	8	11	7	11	7	7	17	9
EBITDA	-	-	-	-	-	-	-	-	-	$-125.63M	$55.46M	$-279.36M	$-179.91M	$-153.63M	$-496.11M	$217.35M	$-820.87M	$-306.95M	$-340.39M	$-212.55M	$-170.82M	$-192.02M	$-13.49M	$-21.89M	$-27.85M	$-14.12M	$-34.63M	$-38.23M	$-41.23M	$-38.23M
Avg Forecast	$-29.17M	$-43.94M	$-157.72M	$-35.25M	$-76.25M	$-54.76M	$-340.35M	$-75.08M	$-239.03M	$-85.66M	$-196.06M	$-65.03M	$-3.42B	$-428.26M	$-630.93M	$227.86M	$-242.38M	$-244.38M	$-283.35M	$-245.02M	$-147.88M	$-168.42M	$-20.60M	$-25.64M	$-1.51M	$-1.94M	$-2.24M	$-38.40M	$-39.38M	$-40.48M
High Forecast	$-27.84M	$-41.94M	$-150.56M	$-34.63M	$-70.02M	$-52.28M	$-324.91M	$-71.67M	$-215.46M	$-81.78M	$-187.16M	$-62.08M	$-2.74B	$-428.26M	$-630.93M	$273.43M	$-242.38M	$-244.38M	$-283.35M	$-196.01M	$-147.88M	$-168.42M	$-20.60M	$-20.52M	$-1.51M	$-1.94M	$-2.24M	$-30.72M	$-31.50M	$-32.38M
Low Forecast	$-31.23M	$-47.04M	$-168.85M	$-35.63M	$-87.08M	$-58.63M	$-364.38M	$-80.38M	$-269.79M	$-91.71M	$-209.90M	$-69.62M	$-4.11B	$-428.26M	$-630.93M	$182.29M	$-242.38M	$-244.38M	$-283.35M	$-294.02M	$-147.88M	$-168.42M	$-20.60M	$-30.77M	$-1.51M	$-1.94M	$-2.24M	$-46.09M	$-47.26M	$-48.57M
Surprise %	-	-	-	-	-	-	-	-	-	1.47%	-0.28%	4.30%	0.05%	0.36%	0.79%	0.95%	3.39%	1.26%	1.20%	0.87%	1.16%	1.14%	0.66%	0.85%	18.49%	7.28%	15.47%	1.00%	1.05%	0.94%

4 analysts predict NVAX's average Quarter EBITDA for Sep 23 to be $-85.66M, with a high of $-81.78M and a low of $-91.71M. This is -254.47% lower than Novavax's previous annual EBITDA (Jun 23) of $55.46M.

Novavax Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	16	8	11	7	11	7	7	17	9
Net Income	-	-	-	-	-	-	-	-	-	$-130.78M	$58.01M	$-293.90M	$-182.25M	$-168.61M	$-510.49M	$203.41M	$-846.28M	$-322.43M	$-352.32M	$-222.72M	$-177.56M	$-197.31M	$-17.52M	$-25.86M	$-31.83M	$-18.04M	$-39.60M	$-43.22M	$-46.35M	$-43.85M
Avg Forecast	$-91.23M	$-64.02M	$104.03M	$-78.42M	$-95.39M	$-126.61M	$267.28M	$258.02M	$-71.70M	$-354.51M	$-213.13M	$234.56M	$-3.53B	$260.12M	$604.26M	$213.24M	$-298.87M	$-647.99M	$-602.39M	$-256.75M	$-369.30M	$287.15M	$-83.92M	$-30.30M	$-176.04M	$-128.37M	$-265.07M	$-43.41M	$-44.28M	$-46.43M
High Forecast	$-85.85M	$-60.24M	$113.58M	$-61.98M	$-66.91M	$-119.15M	$291.81M	$309.62M	$11.71M	$-333.60M	$-200.56M	$281.47M	$-2.82B	$260.12M	$604.26M	$255.89M	$-298.87M	$-647.99M	$-602.39M	$-205.40M	$-369.30M	$287.15M	$-83.92M	$-24.24M	$-176.04M	$-128.37M	$-265.07M	$-34.73M	$-35.42M	$-37.15M
Low Forecast	$-99.60M	$-69.89M	$97.90M	$-92.34M	$-121.02M	$-138.23M	$251.52M	$206.41M	$-188.76M	$-387.04M	$-232.69M	$187.65M	$-4.23B	$260.12M	$604.26M	$170.59M	$-298.87M	$-647.99M	$-602.39M	$-308.09M	$-369.30M	$287.15M	$-83.92M	$-36.36M	$-176.04M	$-128.37M	$-265.07M	$-52.10M	$-53.13M	$-55.72M
Surprise %	-	-	-	-	-	-	-	-	-	0.37%	-0.27%	-1.25%	0.05%	-0.65%	-0.84%	0.95%	2.83%	0.50%	0.58%	0.87%	0.48%	-0.69%	0.21%	0.85%	0.18%	0.14%	0.15%	1.00%	1.05%	0.94%

Novavax's average Quarter net income forecast for Sep 23 is $-354.51M, with a range of $-387.04M to $-333.60M. NVAX's average Quarter net income forecast represents a -711.14% decrease compared to the company's last Quarter net income of $58.01M (Jun 23).

Novavax SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	16	8	11	7	11	7	7	17	9
SG&A	-	-	-	-	-	-	-	-	-	$107.46M	$93.72M	$112.53M	$161.66M	$122.88M	$108.16M	$95.99M	$84.21M	$77.79M	$73.16M	$63.19M	$61.31M	$56.88M	$17.72M	$9.38M	$8.18M	$7.90M	$9.61M	$8.73M	$8.65M	$8.85M
Avg Forecast	$25.09M	$37.80M	$135.67M	$30.33M	$65.60M	$47.11M	$292.79M	$64.59M	$205.62M	$73.69M	$168.66M	$55.94M	$351.09M	$372.90M	$549.37M	$100.63M	$211.04M	$212.79M	$246.72M	$72.84M	$128.76M	$146.65M	$17.94M	$1.23M	$1.31M	$1.69M	$1.95M	$2.81M	$8.26M	$3.84M
High Forecast	$26.86M	$40.47M	$145.25M	$30.65M	$74.91M	$50.43M	$313.45M	$69.15M	$232.08M	$78.89M	$180.56M	$59.89M	$421.31M	$372.90M	$549.37M	$120.76M	$211.04M	$212.79M	$246.72M	$87.41M	$128.76M	$146.65M	$17.94M	$1.23M	$1.31M	$1.69M	$1.95M	$2.81M	$9.92M	$4.61M
Low Forecast	$23.95M	$36.08M	$129.52M	$29.79M	$60.23M	$44.97M	$279.50M	$61.66M	$185.35M	$70.35M	$161.00M	$53.40M	$280.87M	$372.90M	$549.37M	$80.50M	$211.04M	$212.79M	$246.72M	$58.28M	$128.76M	$146.65M	$17.94M	$1.23M	$1.31M	$1.69M	$1.95M	$2.81M	$6.61M	$3.07M
Surprise %	-	-	-	-	-	-	-	-	-	1.46%	0.56%	2.01%	0.46%	0.33%	0.20%	0.95%	0.40%	0.37%	0.30%	0.87%	0.48%	0.39%	0.99%	7.63%	6.24%	4.68%	4.93%	3.11%	1.05%	2.31%

Novavax's average Quarter SG&A projection for Dec 23 is $205.62M, based on 5 Wall Street analysts, with a range of $185.35M to $232.08M. The forecast indicates a 91.35% rise compared to NVAX last annual SG&A of $107.46M (Sep 23).

Novavax EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	16	8	11	7	11	7	7	17	9
EPS	-	-	-	-	-	-	-	-	-	$-1.26	$0.65	$-3.41	$-2.28	$-2.15	$-6.53	$2.66	$-11.18	$-4.31	$-4.75	$-3.05	$-2.70	$-3.21	$-0.30	$-0.58	$-1.13	$-0.74	$-1.69	$-2.20	$-2.80	$-3.20
Avg Forecast	$-0.57	$-0.40	$0.65	$-0.49	$-0.60	$-0.79	$1.67	$-1.06	$-0.45	$-2.21	$-1.33	$-3.46	$-1.01	$1.57	$3.64	$2.69	$-1.80	$-3.91	$-3.63	$-3.60	$-2.23	$1.73	$-0.51	$-0.69	$-1.06	$-0.77	$-1.60	$-2.13	$-2.56	$-0.18
High Forecast	$-0.54	$-0.38	$0.71	$-0.39	$-0.42	$-0.74	$1.82	$-1.00	$0.07	$-2.08	$-1.25	$-3.26	$-0.95	$1.57	$3.64	$2.69	$-1.80	$-3.91	$-3.63	$-3.60	$-2.23	$1.73	$-0.51	$-0.69	$-1.06	$-0.77	$-1.60	$-2.13	$-2.05	$-0.14
Low Forecast	$-0.62	$-0.44	$0.61	$-0.58	$-0.76	$-0.86	$1.57	$-1.16	$-1.18	$-2.42	$-1.45	$-3.78	$-1.11	$1.57	$3.64	$2.69	$-1.80	$-3.91	$-3.63	$-3.60	$-2.23	$1.73	$-0.51	$-0.69	$-1.06	$-0.77	$-1.60	$-2.13	$-3.07	$-0.22
Surprise %	-	-	-	-	-	-	-	-	-	0.57%	-0.49%	0.98%	2.25%	-1.37%	-1.79%	0.99%	6.20%	1.10%	1.31%	0.85%	1.21%	-1.85%	0.59%	0.84%	1.06%	0.96%	1.06%	1.03%	1.09%	17.78%

According to 4 Wall Street analysts, Novavax's projected average Quarter EPS for Sep 23 is $-2.21, with a low estimate of $-2.42 and a high estimate of $-2.08. This represents a -440.77% decrease compared to NVAX previous annual EPS of $0.65 (Jun 23).

Novavax Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INO	Inovio Pharmaceuticals	$1.83	$8.00	337.16%	Buy
VXRT	Vaxart	$0.61	$2.00	227.87%	Hold
MRNA	Moderna	$40.27	$104.90	160.49%	Hold
NVAX	Novavax	$8.51	$20.33	138.90%	Buy
AZN	AstraZeneca	$66.30	$88.00	32.73%	Buy
BNTX	BioNTech SE	$114.13	$126.30	10.66%	Buy

NVAX Forecast FAQ

Is Novavax a good buy?

Yes, according to 18 Wall Street analysts, Novavax (NVAX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 50.00% of NVAX's total ratings.

What is NVAX's price target?

Novavax (NVAX) average price target is $20.33 with a range of $14 to $25, implying a 138.90% from its last price of $8.51. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Novavax stock go up soon?

According to Wall Street analysts' prediction for NVAX stock, the company can go up by 138.90% (from the last price of $8.51 to the average price target of $20.33), up by 193.77% based on the highest stock price target, and up by 64.51% based on the lowest stock price target.

Can Novavax stock reach $13?

NVAX's average twelve months analyst stock price target of $20.33 supports the claim that Novavax can reach $13 in the near future.

What are Novavax's analysts' financial forecasts?

Novavax's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $736.26M (high $795.57M, low $699.11M), average EBITDA is $-546M (high $-519M, low $-590M), average net income is $303.3M (high $415.37M, low $198.68M), average SG&A $470.08M (high $507.94M, low $446.36M), and average EPS is $-0.781 (high $-0.34, low $-1.21). NVAX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $358.5M (high $380.96M, low $343.55M), average EBITDA is $-266M (high $-255M, low $-283M), average net income is $-130M (high $-94.491M, low $-164M), average SG&A $228.89M (high $243.23M, low $219.35M), and average EPS is $-0.81 (high $-0.59, low $-1.024).

Did the NVAX's actual financial results beat the analysts' financial forecasts?

Based on Novavax's last annual report (Dec 2023), the company's revenue was $983.7M, beating the average analysts forecast of $789.24M by 24.64%. Apple's EBITDA was $-567M, missing the average prediction of $-586M by -3.29%. The company's net income was $-545M, beating the average estimation of $-405M by 34.66%. Apple's SG&A was $468.95M, missing the average forecast of $503.91M by -6.94%. Lastly, the company's EPS was $-5.41, missing the average prediction of $-7.457 by -27.45%. In terms of the last quarterly report (Sep 2023), Novavax's revenue was $186.99M, beating the average analysts' forecast of $115.42M by 62.00%. The company's EBITDA was $-126M, beating the average prediction of $-85.664M by 46.66%. Novavax's net income was $-131M, missing the average estimation of $-355M by -63.11%. The company's SG&A was $107.46M, beating the average forecast of $73.69M by 45.82%. Lastly, the company's EPS was $-1.26, missing the average prediction of $-2.215 by -43.12%